ClinicalTrials.gg
CompletedNCT02318836Updated Feb 23, 2018

Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects

A Phase 1 interventional study of Lofexidine Hydrochloride (HCl) tablets in Liver Failure, sponsored by USWM, LLC (dba US WorldMeds). Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-23.

Sponsored by USWM, LLC (dba US WorldMeds) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Liver Failure with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Liver Failure · United States.

Enrollment
23rd of 38
24 · median 31
Started
2014
with 4 others
Phase 1
6 of 49
2 open now
Registered
27th of 49
by date

Among the 49 studies in Liver Failure with a site in United States, this one is the 23rd largest by enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2014, is one of 6 in phase 1, and was the 27th registered.

Liver Failure

190 studies on the registry are indexed under Liver Failure; 33 are open to participants now.

Browse Liver Failure studies →

Open to participants now

6 of the 49 studies in Liver Failure with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Liver Failure studies recruiting now, 11 (50%) set no upper age limit and 8 (36%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Liver Failure with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, parallel-group, single-dose study of lofexidine in 6 adult subjects with mild hepatic impairment (Child Pugh score of 5 6), 6 adult subjects with moderate hepatic impairment (Child Pugh score 7 9), 6 adult subjects with severe hepatic impairment (Child Pugh score 10 15), and 6 control subjects with normal hepatic function with mean age, body mass index (BMI), and gender distribution targeted to be similar to the impaired hepatic function cohorts.

Read the detailed description

This is a Phase 1, open-label, parallel-group, single-dose study of lofexidine in 6 adult subjects with mild hepatic impairment (Child Pugh score of 5 6), 6 adult subjects with moderate hepatic impairment (Child Pugh score 7 9), 6 adult subjects with severe hepatic impairment (Child Pugh score 10 15), and 6 control subjects with normal hepatic function with mean age, body mass index (BMI), and gender distribution targeted to be similar to the impaired hepatic function cohorts. Subjects will be confined to an inpatient facility from the evening before dosing to 144 hours after dosing.

Subjects who successfully complete screening will report to the inpatient facility at an appropriate time the evening before study drug administration (Day 1) to ensure a minimum 10 hour fast. The next morning (Day 1) while still fasting, subjects will receive a single, oral dose of 400 µg lofexidine HCl (two 200 µg tablets). Blood samples will be collected for pharmacokinetic (PK) analysis at multiple time points over the next 144 hours (Day 7). Pooled urine samples will be collected at 0 3 hours, 3 6 hours, 6 12 hours, 12 24 hours, 24 48 hours, 48 96 hours, 96 120 hours and 120 144 hours post-dose. Safety will be assessed by recording adverse events (AEs), measuring vital signs (blood pressure and pulse rate) and clinical laboratory tests (chemistry, hematology, and urinalysis), recording 12 lead safety and Holter electrocardiograms (ECGs), and performing physical exams.

03

Conditions studied

  • Liver Failure

Browse trials for

Keywords

  • hepatic, hepatic impairment, lofexidine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Site will evaluate each subject for criteria in detail, which will include:

  1. Between ages of 18 to 65 years at enrollment with a between 19 and 38 kg/m2, inclusive.
  2. Subject is eligible to enter the study if:

    • Matched control subject: normal hepatic function and free from other illnesses or disease, and medical history, physical examination, laboratory results, and other tests consistent with health, as determined by the Investigator.
    • Subject with mild hepatic impairment: hepatic dysfunction staging system score of 5-6 Points (Stage A) and medical history, physical examination, laboratory results, and other tests consistent with their hepatic impairment, as determined by the Investigator.
    • Subject with moderate hepatic impairment: Child-Pugh hepatic dysfunction staging system score of 7 9 Points (Stage B) and medical history, physical examination, laboratory results, and other tests consistent with their hepatic impairment, as determined by the Investigator.
    • Subject with severe hepatic impairment: Child-Pugh hepatic dysfunction staging system score of 10-15 Points (Stage C) and medical history, physical examination, laboratory results, and other tests consistent with their hepatic impairment, as determined by the Investigator.

Exclusion criteria

Exclusion Criteria:

Site will evaluate each subject for criteria in detail, which will include:

  1. The matched control subject has a history of disease, including cardiovascular, gastrointestinal (GI), renal, hepatic, pulmonary, endocrine, hematologic, vascular, immunologic, metabolic, or collagen disease or the hepatically-impaired subject has a history of clinically significant disease including cardiovascular, GI, renal, pulmonary, endocrine, hematologic, vascular, immunologic, metabolic, or collagen disease.
  2. Abnormal cardiovascular exam at Screening, including any of the following:

    • clinically significant abnormal (e.g., second or third degree heart block, uncontrolled arrhythmia, (Fridericia's correction) interval >450 msec for males and >470 msec for females).
    • heart rate \<45 bpm or symptomatic bradycardia;
    • systolic blood pressure \<90 mmHg or symptomatic hypotension;
    • blood pressure >160/100 mmHg; or
    • prior history of myocardial infarction.
  3. Subjects with hepatic impairment will not be eligible to participate in the study if any of the following exclusion criteria also apply:

    • Significant bleeding diathesis or esophageal bleeding within the last 8 weeks.
    • Evidence of hepatic function deterioration within the last 4 weeks as indicated by liver transaminases, alkaline phosphatase, and gamma-glutamyl transpeptidase or a ≥50% worsening of serum or .
    • History of surgical portosystemic shunt.
    • Prothrombin time >18 seconds.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Normal Hepatic function

    Drug: Lofexidine Hydrochloride (HCl) tablets

  • Active comparator
    Mild Hepatic Impairment

    (Child-Pugh score 5-6)

    Drug: Lofexidine Hydrochloride (HCl) tablets

  • Active comparator
    Moderate Hepatic Impairment

    (Child-Pugh score 7-9)

    Drug: Lofexidine Hydrochloride (HCl) tablets

  • Active comparator
    Severe Hepatic Impairment

    (Child-Pugh score 10-15)

    Drug: Lofexidine Hydrochloride (HCl) tablets

Interventions

  • Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.

06

What researchers measure

Primary outcomes

  1. PK Profile: Cmax, Tmax, AUC, λz, CL/F, T½, CLr, CLd, Ae

    Cmax, Tmax, AUC, λz, CL/F, T½, CLr, CLd, Ae

    Time frame: pre dose until 144 hours post-dose

Secondary outcomes

  1. Adverse events

    Time frame: screening through day 7

  2. Clinical laboratory tests

    hematology, chemistry, urinalysis

    Time frame: screening through day 7

  3. Vital signs

    blood pressure and pulse

    Time frame: screening through day 7

  4. 12-lead ECG

    Time frame: screening through day 7

  5. Holter ECG

    Time frame: pre dose through 8 hours post dose

07

Study locations

1 site
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2014
First posted
Dec 17, 2014
Start
Jun 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Last update
Feb 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02318836
Lead sponsor
USWM, LLC (dba US WorldMeds)
Responsible party
Sponsor
First posted
Dec 17, 2014
Start date
Jun 2014
Primary completion
Oct 2014
Completion
Oct 2014
Last update
Feb 23, 2018

Study contacts

Thomas Marbury, MD
principal investigator · Orlando Clinical Research Center
James Longstreth, PhD
study director · USWM, LLC (dba US WorldMeds)
Charles Gorodetzky, MD, PhD
study director · USWM, LLC (dba US WorldMeds)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lofexidine

Start the discussion